Literature DB >> 15845228

From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis.

Jacques Godfroid1, Axel Cloeckaert, Jean-Pierre Liautard, Stephan Kohler, David Fretin, Karl Walravens, Bruno Garin-Bastuji, Jean-Jacques Letesson.   

Abstract

Brucellosis is not a sustainable disease in humans. The source of human infection always resides in domestic or wild animal reservoirs. The routes of infection are multiple: food-borne, occupational or recreational, linked to travel and even to bioterrorism. New Brucella strains or species may emerge and existing Brucella species adapt to changing social, cultural, travel and agricultural environment. Brucella melitensis is the most important zoonotic agent, followed by Brucella abortus and Brucella suis. This correlates with the fact that worldwide, the control of bovine brucellosis (due to B. abortus) has been achieved to a greater extent than the control of sheep and goat brucellosis (due to B. melitensis), these latter species being the most important domestic animals in many developing countries. The long duration and high cost of treatment of human brucellosis reduces the efficacy of the therapy. There is no human vaccine for brucellosis and the occurrence of brucellosis is directly linked to the status of animal brucellosis in a region. In this context, the Word Health Organization has defined the development of a human vaccine, besides the implementation of control and eradication programs in animals, as a high priority. The pathogenicity for humans of B. suis biovars 1, 3 and 4 is well established, whereas B. suis biovar 2 seems to be less pathogenic. Indeed, although hunters and pig farmers have repeatably experienced infectious contact with B. suis biovar 2 (found in wild boar and outdoor-rearing pigs in Europe), isolation of B. suis biovar 2 from human samples have only been seldom reported. Marine mammal brucellosis, due to two new proposed Brucella species i.e. B. cetaceae and B. pinnipediae, represents a new zoonotic threat but the pathogenicity for humans of the different Brucella species found in cetaceans and pinnipeds still has to be clearly established.

Entities:  

Mesh:

Year:  2005        PMID: 15845228     DOI: 10.1051/vetres:2005003

Source DB:  PubMed          Journal:  Vet Res        ISSN: 0928-4249            Impact factor:   3.683


  148 in total

1.  Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice.

Authors:  Deyan Luo; Bing Ni; Peng Li; Wei Shi; Songle Zhang; Yue Han; Liwei Mao; Yangdong He; Yuzhang Wu; Xiliang Wang
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  The Brucella suis type IV secretion system assembles in the cell envelope of the heterologous host Agrobacterium tumefaciens and increases IncQ plasmid pLS1 recipient competence.

Authors:  Anna Carle; Christoph Höppner; Khaled Ahmed Aly; Qing Yuan; Amke den Dulk-Ras; Annette Vergunst; David O'Callaghan; Christian Baron
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Brucella abortus phosphoglyceromutase and dihydrodipicolinate reductase induce Th1 and Th2-related immune responses.

Authors:  Zhiqiang Li; Hui Zhang; Jinliang Zhang; Li Xi; Guangli Yang; Shuli Wang; Qingfeng Zhou; Xiaogen Zhang; Junbo Zhang
Journal:  World J Microbiol Biotechnol       Date:  2018-01-04       Impact factor: 3.312

4.  Brucellosis epidemiological and clinical aspects (Is brucellosis a major public health problem in Bosnia and Herzegovina?).

Authors:  Sajma Krkić-Dautović; Snjezana Mehanić; Merdina Ferhatović; Semra Cavaljuga
Journal:  Bosn J Basic Med Sci       Date:  2006-05       Impact factor: 3.363

5.  Novel IS711 chromosomal location useful for identification of marine mammal Brucella genotype ST27, which is associated with zoonotic infection.

Authors:  Axel Cloeckaert; Nelly Bernardet; Mark S Koylass; Adrian M Whatmore; Michel S Zygmunt
Journal:  J Clin Microbiol       Date:  2011-08-31       Impact factor: 5.948

6.  B Cells Inhibit CD4+ T Cell-Mediated Immunity to Brucella Infection in a Major Histocompatibility Complex Class II-Dependent Manner.

Authors:  Alexis S Dadelahi; Carolyn A Lacey; Catherine A Chambers; Bárbara Ponzilacqua-Silva; Jerod A Skyberg
Journal:  Infect Immun       Date:  2020-04-20       Impact factor: 3.441

7.  Brucellosis in Occupationally Exposed Groups.

Authors:  Smita S Mangalgi; Annapurna G Sajjan; Shivajirao T Mohite; Shivali Gajul
Journal:  J Clin Diagn Res       Date:  2016-04-01

8.  Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.

Authors:  Karina A Pasquevich; Silvia M Estein; Clara García Samartino; Clara García Samartino; Astrid Zwerdling; Lorena M Coria; Paula Barrionuevo; Carlos A Fossati; Guillermo H Giambartolomei; Juliana Cassataro
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

9.  Brucellosis of the lung: case report and review of the literature.

Authors:  Dirk Theegarten; Sven Albrecht; Martin Tötsch; Helmut Teschler; Heinrich Neubauer; Sascha Al Dahouk
Journal:  Virchows Arch       Date:  2007-10-20       Impact factor: 4.064

10.  Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella.

Authors:  Jerome S Harms; Marina A Durward; Diogo M Magnani; Gary A Splitter
Journal:  J Immune Based Ther Vaccines       Date:  2009-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.